Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript

Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript May 2, 2024

Ardelyx, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.13. Ardelyx, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Good day and welcome to the Ardelyx First Quarter 2024 Earnings Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Caitlin Lowie, Vice President of Corporate Communications and Investor Relations at Ardelyx. Please go ahead.

Caitlin Lowie: Thank you. Good afternoon and welcome to our first quarter 2024 financial results call. During this call, we will refer to the press release issued earlier today which is available on the Investors section of the company’s website at ardelyx.com. During this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those described. We encourage you to review the risk factors in our most recent quarterly report on Form 10-Q that was filed today and can be found on our website at ardelyx.com. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change.

Our President and CEO, Mike Rob, will begin today’s call with opening remarks and an overview of the company’s progress during the first quarter of 2024. Next, Susan Rodriguez, Chief Commercial Officer; will provide an update on the performance of IBSRELA and XPHOZAH. Justin Renz, Chief Financial and Operations Officer, will conclude today’s prepared remarks with a review of the company’s financial performance during the first quarter ended March 31, 2024, before we open the call to questions. With that, let me pass the call over to Mike.

Mike Raab: Good afternoon, everyone and thank you for joining us on this call. Q1 earnings always seem to come quickly after we report our Q4 results. And yet, as usual, a lot has happened since we last provided you an update. First, XPHOZAH performance out of the gate following the launch in November continues at a remarkable pace. This is a first-in-class product in a therapeutic area that has seen no innovation in decades. The response from the prescribing community clearly demonstrates the significant unmet need among this patient population. XPHOZAH is an important new option for physicians to help patients whose serum phosphors remains elevated despite best efforts. All demand indicators are favorable. Prescribers are eager to learn more about XPHOZAH’s blocking mechanism and are working to identify potential candidates for therapy.

Like IBSRELA, Ardelyx assist in supporting prior authorizations and helping patients take advantage of our affordability programs. Patients are accessing the drug and the feedback is that patients are seeing sustained reductions in their serum phosphorus [ph]. We are focused on ensuring prescribers are aware and educated on XPHOZAH and ensuring patients have access to treatment. As you can see by our performance, it’s going very well. IBSRELA continues to perform strongly, providing an important option to again address a large unmet need among IBS-C patients. We believe that this can be a $1 billion product and on the path to achieving that piece we expect full year net sales revenue for 2024 to be between $140 million and $150 million. As I consider the first quarter performance, the underlying demand metrics and fundamentals of the business are robust and continue to demonstrate growth in new and repeat riders and new and refill prescriptions.

Our reported revenue reflects demand growth, offset by the impact of seasonality which is standard across the industry that we experienced during this first quarter. Importantly, our cash position remains strong, resulting from our revenue, the third tranche of debt from our partnership with SLR and thoughtful management of our expenses. We are at an exciting time in our evolution as a company and our top priority is to build upon the growth momentum of IBSRELA and XPHOZAH. Now, I will turn the call over to Susan to discuss first quarter performance for both of our products. Susan?

Susan Rodriguez: Thank you, Mike. It is great to be here today to discuss the commercial performance for IBSRELA and XPHOZAH. Our performance reflects strong execution of our disruptive commercial approach for both first-in-class products which centers on targeting the high-volume writers in our disease areas, driving identification of patients in need of a novel treatment option as their response to existing treatment options is deemed to be inadequate. And enabling patient access and affordability with favorable coverage policies that define the path to access prior authorization support and patient support programs. Let me begin with IBSRELA. Our confidence in this product is driven by the strength of the fundamentals driving IBSRELA’s performance.

HCPs are evolving their treatment practice now that they have expanded treatment options for their IBS-C patients following the launch of IBSRELA. Based on the favorable clinical response they are seeing and confidence in the path to access, HCPs are increasingly identifying patients in need of a novel treatment option. During the first quarter, we saw increases across all key demand parameters for the product, including growth in new writers and repeat writers as well as growth in new prescriptions and refill prescriptions. We are very encouraged by the continued growth of these key demand metrics despite IBSRELA being impacted by first quarter seasonality that is commonly seen across the industry linked to insurance plan resets and prior authorization renewal processes.

During the first quarter, we began the process to expand the IBSRELA dedicated sales force footprint from 64 territories to 124 territories. We experienced a strong response to the job posting, attracting sales talent with extensive GI experience who are motivated and enthusiastic to join the IBSRELA sales team and be part of disrupting the IBS-C market with an innovative therapy. Hiring, training and full deployment of this team is on track to be completed by the end of the second quarter. This sales force footprint puts us in a strong position to capitalize on the promotion sensitivity we have seen across our high-riding HCP targets to further drive increases in new writers as well as drive expanded use across our growing writer base who are continuously broadening their view of patients who are candidates for IBSRELA.

The fundamental drivers behind IBSRELA are strong and we anticipate continued quarter-over-quarter growth with our expectations for the 2024 performance consistent with our stated guidance. Turning to XPHOZAH. We are extremely pleased with the nephrology community’s response to this first-in-class phosphate absorption inhibitor. It is clear that patients have been in need of a new option to manage their phosphorus when binders were insufficient or not well tolerated. Our dedicated nephrology sales team, comprehensive blocking messaging campaign, speaker and promotional programs and omnichannel initiatives are driving high interest and early uptake of XPHOZAH. Nephrologists are responding favorably to the novel blocking mechanism and clinical data profile are pleased with their early clinical experience, encouraged by the defined coverage policies and increasingly integrating this novel blocking mechanism product into the therapeutic regimen for their patients.

The feedback we regularly receive from the field is that physicians are seeing that their XPHOZAH treated patients, many of whom have been continuously outside of target ranges, are reflecting consistent improvement in serum phosphorus levels and that these levels are being maintained. We are also hearing that patients are responding favorably to the dosing profile and that HCPs are pleased with the flexibility they have in adapting the patient’s treatment regimen. Where they can add XPHOZAH to the patient’s existing binder regimen or they can add XPHOZAH and reduce the patient’s binder regimen or they can add XPHOZAH and fully discontinue the patients binder regimen. HCPs are adopting XPHOZAH and are adapting regimens based on the needs of the patients.

We are very pleased with the $15.2 million in sales we reported for XPHOZAH during the first quarter. This performance is consistent with the uptick indicators we are seeing in the field. Our sales force is experiencing highly engaged meaningful discussions with our target HCPs who are eager to learn about XPHOZAH. Nephrology HCPs are rapidly identifying patients who they believe can benefit from therapy, reporting to us that they may have many patients outside of target ranges despite treatment with binders or are intolerant of binders therapy. HCPs are pleased with the clinical response they are seeing and patients are responding favorably to the treatment experience. Coverage policies are being defined that outline a path to access by our prior authorization attesting to the fact that the patient has been treated with binders and inadequately responding or unable to tolerate the therapy.

HCPs are seeing that when prior authorizations are submitted for patients meeting the criteria, patients are gaining access to XPHOZAH. Nephrology HCPs and their office staff are responding favorably to our specialty pharmacy distribution network as well as to our comprehensive patient services offering, Ardelyx Assist that further enable patient access through prior authorization support and patient engagement with the affordability programs available to them. Our own internal metrics are supported by external research conducted by Spherix [ph], who is tracking the launch of XPHOZAH. According to the April 2024 launch dynamics report nearly all of the 77 surveyed nephrologists, 98% rate XPHOZAH as an advance over currently available hyperphosphatemia therapy.

In addition, 56% of the surveyed nephrologists reported using XPHOZAH and of those, again, 98% report satisfaction with treatment. The research demonstrates that awareness is high among the nephrology community interest and intent to adopt is high and satisfaction with the treatment is high among users. We will continue to build upon our launch momentum, capitalizing on the high nephrology awareness of the number of patients that are in need of a new treatment option despite treatment with binders and their intent to adopt XPHOZAH for these patients. Our go-to-market strategy is working. We have established a strong presence in nephrology offices across the country and HCPs are responding favorably to the novel blocking mechanism and clinical data profile.

They are identifying patients that could benefit from XPHOZAH therapy and with coverage policies in place, patients are gaining access and responding favorably to treatment. We are pleased with the performance thus far and our focus on continuing this growth momentum. We have several exciting months ahead as we will have strong commercial and clinical presence across key annual medical conferences for both IBSRELA and XPHOZAH, where we’ll have the opportunity to present more clinical trial data on our products, connect with the prescribing community and deepen our relationship with patients. I look forward to continuing to share updates with you in the future. With that, I will hand it to Justin.

Justin Renz: Thank you, Susan. I’m very pleased to be with you today to discuss the first quarter performance we reported which included meaningful progress towards our IBSRELA net sales revenue guidance, a strong launch of XPHOZAH, careful management of our finances and a strong cash position. Let’s start with revenue. As you saw in this afternoon’s release, we reported significant year-over-year growth, bringing our total first quarter product-related revenue to $45.6 million compared to $11.4 million in the first quarter of 2023. Net product sales revenue for IBSRELA was $28.4 million during the first quarter of 2024, more than doubling the $11.4 million in revenue we reported during the same period in 2023 and a 1% quarter-over-quarter growth compared to the fourth quarter of last year.

Volume demand grew for IBSRELA during the first quarter which was offset by deductions associated with the reset of annual prescription drug plans. Most notably, this was related to our commercial co-pay program. The impact of the commercial co-pay program is most significant in the first quarter when most commercial health care plans reset and patients have higher out-of-pocket requirements. As patients fill prescriptions throughout the year and begin meeting their deductible requirements, our expenses related to the commercial co-pay program declined. Our gross to net deduction for IBSRELA during the first quarter was in line with our expectations at 33.5% and comparable to the 33.7% we saw in the first quarter of 2023. We expect this percentage to improve as the year progresses as it did last year.

In addition, we saw the anticipated impact of the prior authorization renewal process that occurs at the start of the calendar year for many health care plans. The strong demand and expected improvement in gross to net deductions reinforce our confidence in the ongoing performance of IBSRELA. As such, we continue to expect that full year U.S. IBSRELA net product sales revenue will be between $140 million and $150 million. XPHOZAH had an exceptional first full quarter performance as we are reporting $15.2 million in net sales revenue, driven by the meaningful demand for this product. Our gross to net deduction came in favorably for XPHOZAH at 23.8%. As we progress into the launch of XPHOZAH and learn more about the patient mix that drives the associated gross to net deduction, we will share more.

In addition, we had $2.5 million in combined licensing and product supply revenue. We are very pleased with our top line results during the quarter which demonstrated the growth momentum Mike and Susan both spoke to. At the same time, we continue to be thoughtful on how we manage our expenses. Research and development expenses were $10.6 million compared to $9.1 million during the first quarter of 2023. Selling, general and administrative expenses were $53 million for the first quarter compared to $26.8 million for the same period of 2023. The increase was related to launch activities for XPHOZAH as well as continued investments to grow IBSRELA which we made throughout last year. Importantly, our costs were comparable to our spending in the fourth quarter of 2023.

We expect to complete the current expansion of the IBSRELA sales force that Susan previously mentioned by the end of the second quarter. Substantial top line growth, combined with thoughtful cost management, resulted in a net loss of approximately $26.5 million or $0.11 per share in the first quarter of 2024, compared to a net loss of $26.8 million or $0.13 per share in the same period of 2023. The net loss for the first quarter of 2024 included $9.3 million in combined noncash expenses from share-based compensation and noncash interest expense related to the sale of future royalties. As of March 31, 2024, we had total cash, cash equivalents and short-term investments of $202.6 million as compared to $184.3 million at the end of 2023. This includes $49.8 million in net proceeds that we drew in March from our term loan agreement with SLR Capital.

We are very pleased with our performance during the first quarter, driving top line growth across all reported revenue lines, planning for success, investing in our supply chain managing our operating expenses and strengthening our cash position. We will continue to be thoughtful with how we deploy capital while focusing on maximizing shareholder value. And with that, I’ll turn it back to Mike.

Mike Raab: Thanks, Justin. I hope that what you took away from our performance during the first quarter is at one, we continue to have high expectations for IBSRELA, including $140 million to $150 million in net sales revenue this year and on the path to at least 10% market share and $1 billion in annual revenue. Two, XPHOZAH launch progress is exceptional and it is already beginning to disrupt the hyperphosphatemia market where there remains significant unmet needs among patients. And finally, we’re in a strong cash position to invest in growth. We have a lot of important work ahead of us and we have the team in place who is able to deliver. I look forward to sharing our progress with you over the coming quarters. And I will now open the call to questions. Operator?

See also 20 States with the Highest Student Loan Debt and 24 Profitable Outdoor Business Ideas to Start In 2024.

Q&A Session

Operator: [Operator Instructions] The first question comes from Chris Raymond with Piper Sandler.

Chris Raymond: And congrats on the great success here with XPHOZAH Just — maybe one question on that and a follow-up as well. So I know you guys are early in the launch and you’ve already established sort of a cadence here for guidance after having a number of quarters that you’ve set with IBSRELA. But — just — but the magnitude of the speed is obviously more than any of the expected. Can you provide maybe any sort of color here. I think everybody sees the script data and if folks were following that, they’re even surprised. Those who have been following the script data closely are surprised by the number. Any sort of color in terms of the uptake in what we should be thinking in terms of the implications for the next several quarters — a couple of quarters anyway?

And then maybe the follow-up is, I know, Mike, you’re not in the business of predicting legislation but in the absence of sort of any progress in terms of pushing the phosphate binders into the bundle, pushing that off — at what point do you start maybe planning for that as a reality?

Mike Raab: So Chris, thank you for the questions. I guess, first of all, I hope by now you can tell that we’re not quitters. And that we see what we’re doing for patients and the uptick that we see with XPHOZAH is and has been absolutely worth the fight that we’re fighting. I think as you see with what we’ve done with IBSRELA, these IBS-C patients as well deserve the attention that we’re giving them. What you saw with Ardel [ph] is we need and we expect to have roughly 4 quarters under our belts before we give guidance. We don’t want to get over our skis. We’re excited and thrilled by this performance, the anticipation for the drug out there, the enthusiasm our [indiscernible] are saying in the field is remarkable. The ability that we have in helping people through the prior authorization process through our dialysis [ph] assists is working extraordinarily well based on some learnings that we got through with IBSRELA.

So although I would like to clear answer on both of those, I’m sorry. I’m sure you understand that I can’t.

Operator: The next question comes from Yigal with Citi.

Yigal Nochomovitz: Susan, I just had a few questions on the commercial franchise. Regarding IBSRELA, can you comment on the percent that were new writers versus repeat writers in the quarter? And then with the almost doubling in the territories, how do you expect that to scale in terms of the size of the base of the prescribing physician community? And then with XPHOZAH, you nicely articulated 3 buckets, the ones where you add XPHOZAH and get them to go, ones where you can add and then reduce the binder and then even ad XPHOZAH and potentially remove the binder altogether? Do you have any anecdotal or early evidence or data to discuss sort of roughly what percent fall into each of those 3 scenarios?

Susan Rodriguez: Thanks, Yigal. Thanks for the question. In terms of the new and repeat writing, we have not disclosed the specifics in terms of those percentages. But what I can tell you, that’s a really important metric to track, is just the persistence of new writers being generated weekly, monthly, quarterly. And what we’re seeing since launch is that this has been persistent with new writers being generated constantly on a weekly, monthly and quarterly basis. So seeing that persist really gives us great confidence in the momentum and our guidance for this year. In terms of repeat writing, what’s important to note there is that now that we’re several quarters into launch, we have the data to show that new writers right again.

So we’re seeing that repeat writing is also persistent where the growth opportunity is, is in continuing to drive that new writer growth but then also amongst that growing wider base, really growing depth of writing. So these repeat writers could write more often and for more patients. And what our sales force is executing on is really driving that broader view based on the foundation of positive experience they’ve had to date of patients that now really need to be considered as candidates for IBSRELA because they do have persistent systems, have been tried on other things and now physicians have seen that there is a path to access and that patients are responding well. So they’re broadening their view on potential candidates and that really an important growth opportunity for us as well.

In terms of the sales force impact, that’s exactly why we believe it was critical to continue to invest in our sales force footprint because our experience to date shows that the space is quite promotion sensitive. So the more we call on doctors, the more they write IBSRELA. We see that relationship, the more they engage in all of our omnichannel initiatives and in our program, the more IBSRELA they write. So — so expanding our footprint from 64 to 124 really gives us an opportunity to get those — get into those HCP offices more frequently to continue to drive that expanded writing and really capitalizing on the fact that they are broadening their view on patients who are candidates for XPHOZAH. And at the same time, can also continue to penetrate our target space and generate new writers.

So really being able to execute — to achieve both.

Yigal Nochomovitz: Okay. Great. And then if you could comment on the XPHOZAH question, if you have any data there regarding the way it’s bucketing reducing the binder versus [indiscernible].

Susan Rodriguez: Yes, not specifically from a percentage standpoint, Yigal. But what we’re hearing persistently is that all nephrology — in general, nephrologists are just commenting on the flexibility. And that’s what’s really exciting because that means that, that patient group that they identify that they believe is inadequately managed on binders or don’t tolerate binders, they see XPHOZAH because of its complementary MOA blocking mechanism of action as a drug that, that patient could benefit from there. And they’re — and they don’t have an ingoing concern around how it gets integrated because they can be flexible on initiating therapy and then perhaps some of them are initiating, tracking and then taking them off. Some of the binders, some of them just cut the binders right away.

Some of the time, they just eliminated entirely, as I mentioned in my narrative. So what we hear more is just that with each doctor is actually using the drug with this level of flexibility and that they see that as a way to really be able to realize the benefits of novel mechanism XPHOZAH across their patients that they see are inadequately managed.

Mike Raab: Yigal, it’s Mike. Just one additional comment with that is, I think, as we spoke earlier, in other calls is you never had multiple mechanisms like you do with some many other diseases to manage what the drugs are trying to address. So it’s not going to be a static ratio in any given patient. There’s going to be an intern intrapatient variability depending upon their serum phosphorus. There’s now flexibility and tools for these physicians to finally get phosphors in the target range that they’re looking for. So I think that’s an evolve. And as we understand that better in the coming quarters, we’ll certainly share it.

Operator: The next question comes from Louise Chen with Cantor.

Louise Chen: So first question I wanted to ask you about was XPHOZAH and the $15.2 million. Is that all demand sales? Or is there any stocking in there? And secondly, just back on the [indiscernible], if it doesn’t move through then is that $1 billion of peak sales you have for IBSRELA at risk or that is regardless of whether or not happens [ph]?

Mike Raab: Yes. I mean there are two different product lines in different patient populations. So our guidance with IBSRELA is independent of that. But thanks for asking that. As it relates to stocking, let me ask Justin to address that.

Justin Renz: Thank you, Louise. It has been really a just in time, if you will, approach with XPHOZAH. So through our network, we’ve seen very low inventory rates since launch in November. So I would say this is absolutely demand of the patients and not at all any stocking, very limited to roughly between 1 and 2 weeks at MAX in the channel.

Operator: The next question comes from Ryan Deschner with Raymond James.

Ryan Deschner: Two good questions for me. At this point, I was wondering what the breakdown is looking like so far between patients getting access to XPHOZAH through Medicare versus non-Medicare? And then comparing the how much of XPHOZAH’s strong start are you attributing to the differences in market dynamics versus differences in your commercialization strategy? In other words, is your commercialization strategy for XPHOZAH markedly different from that of the early IBSRELA launch? Or is the main driver more related to differences and things like that unmet need, patients rate, et cetera?

Mike Raab: Yes. Ryan, thanks for the question. The easy answer is, of course, it’s our very, very unique and disruptive commercialization approach. No kidding. Is — I think what we do here and Susan can address it in greater detail, it truly is one about having really good drugs that are making a difference for these patients, having a commercial team that knows how to communicate that to the omnichannel initiatives and remarkable sales team with feet on the ground, talking to physicians about what these drugs can do for their patients because these drugs work. Susan?

Susan Rodriguez: Yes. So I would say exactly to Mike’s point, our go-to-market strategy, actually, there are really very important parallel between IBSRELA and XPHOZAH and the novel MOA and the fact that there’s limited options and the fact that there’s patients in need of novel options. So where I see — what’s an important distinction is that for XPHOZAH, we went into the market with a very, very ingoing high level of awareness of XPHOZAH across the nephrology target base and high interest and intent to adopt and high level of awareness on the range of the patients that they see that they have challenges in managing serum phosphorus on binder therapy. So I think there was a higher level of market awareness about both the product and the unmet need.

Whereas with IBSRELA, while it’s a parallel situation where patients have limited options and are inadequately managed and in need of a novel option and our go-to-market approach, it’s really our promotion and our education on our target base that really got them to begin to identify, Wow, yes, patients are inadequately managed. We never had another option. Now that we have another option, we’re increasingly identifying these patients. We’re actually engaging in dialogue with these patients. And now we’re expanding the way we treat and using IBSRELA for those patients in adeptly managed. So there was a little bit more market need education required on the IBSRELA side. And those are the only difference is, path to access is the same and the coverage policy that they’re being defined or have also been favorable on both sides.

Ryan Deschner: Got it. And then on the Medicare versus non-Medicare breakdown for the first quarter?

Mike Raab: Susan?

Susan Rodriguez: Yes. Thank you, Mike. Yes, so right now, it’s actually really interesting being on the market now for a full quarter that we can see from our IQVIA data, what the percent mix is for the XPHOZAH prescription. And on average, between 55% and 60% is Medicare and the remainder is non-Medicare.

Operator: The next question comes from Dennis Ding with Jefferies.

Dennis Ding: Few questions for me, if I may. On gross to net for XPHOZAH, this was definitely better than what people expected in the first quarter. So how does this evolve through the year and we should use the 23% as the new base going forward? And then secondly, I want to take another stab at this question. But on [indiscernible] ’24, if the bill is to be signed into law in the first half of ’25, XPHOZAH would need to go into TDAPA [ph]. But then if the bill gets signed, XPHOZAH would need to come back out of TDAPA [ph]. Can you perhaps shed some light on that process and some of the logistics around that?

Mike Raab: Dennis. Yes, let me just address that quickly. Currently, I think as we’ve said, our intent is to enter the TDAPA [ph]. I think the specifics of what you’re just describing, that’s going to play out over time. But our current intent is to go through the process and as we hope and the work that we’re doing and what Bunny Carter is doing and others on the Hill [ph], is understanding how important this medicine is for patients. This is a good policy. It’s the right thing to do to ensure that patients get access to a drug that’s already beginning to make a difference in many, many lives of dialysis patients. So the work continues and the specifics about how things come in and out based upon these next 6 months or more, we’ll get that to you as we also learn. And Justin, if you can address the gross to net.

Justin Renz: Thanks, Mike. Dennis, in the first quarter, XPHOZAH gross to net deduction was 23.8%. It obviously is very early in the launch and also the first quarter of the calendar year. So as Susan articulated, our Medicare non-Medicare split is around 55% to 60% Medicare and the rest non-Medicare. We’re still awarding the patient mix. This is going to drive the gross-to-net ratio through the course of the year. So as a reminder, like I said, it’s our first full quarter. We’re currently estimating that maybe it will slightly increase over the next few quarters. But in general, we believe for the rest of this year, it will be in the mid-20s range. And we will obviously comment more [indiscernible] when we have greater clarity.

Operator: The next question comes from Roanna Ruiz with Leerink Partners.

Roanna Ruiz: One for XPHOZAH, could you talk a bit about what the early adopter patients look like in terms of their main features? And what’s really encouraging physicians to find them and identify them as optimal candidates for XPHOZAH?

Mike Raab: Yes, I’ll ask Susan to address it but the realities are, they are not that hard to find. When we know [indiscernible] patients are out of range. And they’ve been waiting for something like this. So it’s fine [ph]. As you asked the question, do you have patients above? The answer is, of course, yes and then we move forward. Susan, sorry, I took the…

Susan Rodriguez: Yes. No, no, you’re absolutely right. But I think in terms of — I appreciate your question on who are these early patients we’re getting. And I think to Mike’s point, first of all, important to know that these phosphorus lovers are tracked very closely. So nephrologists have like an ongoing understanding of their patient base and where their phosphorus are. So what we’re seeing in terms of the patients that are being initiated on XPHOZAH right away are those that the nephrologists had in mind that they know historically, they’ve really had challenges in keeping them in target ranges. That’s who we’re getting now. And what’s really important is we continue to execute is now that the XPHOZAH is available to really make sure that the nephrologist begins to adapt their behavior and turn to XPHOZAH when possible, looking at their patients that are outside of target ranges.